MaRS Innovation operates as a commercialization agent for the intellectual properties in the areas of therapeutics, medical device, diagnostic imaging, information, communications, and manufacturing and clean technologies to the inventors in Canada. The company has strategic partnerships with GlaxoSmithKline Inc.; CML HealthCare Inc.; Baxter International Inc.; and Pfizer Inc. MaRS Innovation was incorporated in 2008 and is based in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2008
The Ontario Government, University of Toronto, and MaRS Discovery District Announce Collaboration with Janssen to Launch Johnson & Johnson Innovation, JLABS Incubator Model in Toronto
Sep 8 15
The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto. The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies. As the first JLABS to open outside the United States, JLABS at Toronto joins a network of life science facilities that are based throughout the United States in San Diego, San Francisco, South San Francisco, Boston and Houston. These facilities are home to over 100 early-stage companies advancing bio/pharmaceutical, medical device, consumer and digital health programs. JLABS at Toronto will be located at MaRS Discovery District, occupying one floor of the West Tower. JLABS at Toronto will provide startups with many of the advantages of being part of an established innovation centre - such as access to talent and mentors, large existing firms and research universities, capital and convergence opportunities with other sectors. When complete, the 40,000-square foot facility will include cutting-edge, modular and scalable lab space, equipment, with access to scientific, industry and capital funding experts. JLABS at Toronto is a collaboration among Johnson & Johnson Innovation, The University of Toronto, MaRS Discovery District, Janssen Inc., MaRS Innovation, and the Government of Ontario. Hospital participants include: Centre for Addiction and Mental Health, The Hospital for Sick Children (SickKids), Sinai Health System, St. Michael's Hospital, Sunnybrook Health Sciences Centre, and University Health Network. Construction of JLABS at Toronto will begin in 2015, and is expected to be ready for occupancy by spring 2016. Over the coming months, best practices pioneered at other JLABS will be adopted to accelerate the impact and success of this new collaboration.
Encycle Therapeutics Inc. Announces Partnership with MaRS Innovation to Develop Molecule to Tackle Inflammatory Bowel Disease
Nov 10 14
Encycle Therapeutics Inc. in partnership with MaRS Innovation which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR), the Université de Montréal (UdeM) and MaRS Innovation. The agreement brings a significant investment to fund Encycle Therapeutics' development work, giving IRICoR an equity position and expanding MaRS Innovation's equity stake. Cumulatively, Encycle Therapeutics has secured more than $2.5 million to advance its drug development platform. The partnership will fund and deploy a number of experienced medicinal chemists at UdeM's Institute for Research in Immunology and Cancer (IRIC) to optimize Encycle Therapeutics' lead molecule. Additional studies will be conducted at the biopharmacy platform of the Faculty of Pharmacy of the UdeM, while Encycle Therapeutics conducts other project-related activities, including pre-clinical efficacy studies.
Johnson & Johnson Innovation, Janssen Inc. Announce New Collaborations with NEOMED and MaRS Innovation
Dec 10 13
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health. Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.